Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Taiho Oncology Inc.
Sponsor

Taiho Oncology Inc.

United States 101 Carnegie Center Suite 300, 08540-6231, United States

About the sponsor

Acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are central areas of interest, with studies extending to related relapsed or refractory disease settings and combinations used in hematologic oncology.

  • Acute myeloid leukemia (AML)
  • Myelodysplastic syndromes (MDS)
  • Chronic myelomonocytic leukemia (CMML)
  • Relapsed/refractory hematologic disease

Research activity in this area includes oral decitabine/cedazuridine programs and other regimens directed at bone marrow disorders.

About Specializations

Taiho Oncology Inc. runs clinical trials in conditions such as Non-small cell lung cancer, Myelodysplastic syndrome, Chronic myelomonocytic leukaemia, Acute myeloid leukaemia, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

15 clinical trials

Chronic myelomonocytic leukaemia+1

Recruiting

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Taiho Oncology Inc.

Acute myeloid leukaemia+3

Recruiting

Title: Long-term treatment study of oral decitabine and cedazuridine combination for patients with AML, MDS, CMML, or solid tumors who previously received ASTX727

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Neoplasm malignant

Recruiting

Study on the Long-Term Safety of Futibatinib and Fulvestrant for Patients with Malignant Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Taiho Oncology Inc.

Non-small cell lung cancer

Recruiting

Study on the Safety and Effectiveness of Zipalertinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Specific EGFR Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Digoxin
  • Sponsor:Taiho Oncology Inc.

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Non-small cell lung cancer

Not recruiting

A study to evaluate how the body processes zipalertinib in healthy adult men

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:[14C]ZIPALERTINIB
  • Sponsor:Taiho Oncology Inc.

Acute myeloid leukaemia

Not recruiting

Pharmacokinetic, Safety, and Efficacy Evaluation of ASTX727 and Venetoclax in Adult Patients with Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Diffuse large B-cell lymphoma+4

Not recruiting

Study on the Safety and Effects of Tolinapant in Patients with Advanced Solid Tumors and Lymphomas

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tolinapant Lactate
  • Sponsor:Taiho Oncology Inc.

Myelodysplastic syndrome

Not recruiting

Study of decitabine and cedazuridine combination in patients with lower-risk myelodysplastic syndromes

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Neoplasm

Not recruiting

Study of Futibatinib with Pembrolizumab and Chemotherapy for Patients with Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Taiho Oncology Inc.

Transitional cell carcinoma+1

Not recruiting

Study of Futibatinib and Pembrolizumab for Patients with Advanced or Metastatic Bladder, Urethra, or Pelvis Cancer Not Suitable for Platinum Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Futibatinib
  • Sponsor:Taiho Oncology Inc.

Cholangiocarcinoma

Not recruiting

Study of Futibatinib for Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Futibatinib
  • Sponsor:Taiho Oncology Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.